199 related articles for article (PubMed ID: 21568074)
1. [The importance of antenatal immunoprophylaxis for prevention of hemolytic disease of the fetus and newborn].
Starcević M; Mataija M; Sović D; Dodig J; Matijević R; Kukuruzović M
Acta Med Croatica; 2011 Mar; 65(1):49-54. PubMed ID: 21568074
[TBL] [Abstract][Full Text] [Related]
2. Receipt of RhD-positive whole blood for life-threatening bleeding in female children: A survey in alloimmunized mothers regarding minimum acceptable survival benefit relative to risk of maternal alloimmunization to anti-D.
Sherwood MR; Clayton S; Leeper CM; Yazer M; Moise KJ; Granger ME; Spinella PC
Transfusion; 2024 May; 64 Suppl 2():S100-S110. PubMed ID: 38563495
[TBL] [Abstract][Full Text] [Related]
3. Antenatal
Clausen FB
Immunohematology; 2024 Apr; 40(1):15-27. PubMed ID: 38739027
[TBL] [Abstract][Full Text] [Related]
4. Neonatal and Obstetrical Outcomes of Pregnancies Complicated by Alloimmunization.
Bahr TM; Tweddell SM; Zalla JM; Dizon-Townson D; Ohls RK; Henry E; Ilstrup SJ; Kelley WE; Ling CY; Lindgren PC; O'Brien EA; Christensen RD
Pediatrics; 2024 Jun; 153(6):. PubMed ID: 38784990
[TBL] [Abstract][Full Text] [Related]
5. Terminating Routine Cord Blood RhD Typing of the Newborns to Guide Postnatal Anti-D Immunoglobulin Prophylaxis Based on the Results of Fetal RHD Genotyping.
Stensrud M; Bævre MS; Alm IM; Wong HY; Herud I; Jacobsen B; de Vos DDJA; Stjern HE; Sørvoll IH; Barane JB; Bagås TE; Rasmussen M; Ulvahaug N; Wamstad V; Tomter G; Akkök CA
Fetal Diagn Ther; 2023; 50(4):276-281. PubMed ID: 37379821
[TBL] [Abstract][Full Text] [Related]
6. Preventing RhD haemolytic disease of the newborn. Revised guidelines advocate two doses of anti-D immunoglobulin for antenatal prophylaxis.
Lee D
BMJ; 1998 May; 316(7144):1611. PubMed ID: 9596614
[No Abstract] [Full Text] [Related]
7. Effect of Anti-D titers in RhD-negative pregnant women on fetuses and newborns: A retrospective study.
Tang TH; Guo CY; Li XY; Hu YX; Liu WK; Yu MX
Pediatr Neonatol; 2024 May; 65(3):288-292. PubMed ID: 37957047
[TBL] [Abstract][Full Text] [Related]
8. Hemolytic disease of the fetus and newborn due to Rh(D) incompatibility: A preventable disease that still produces significant morbidity and mortality in children.
Pegoraro V; Urbinati D; Visser GHA; Di Renzo GC; Zipursky A; Stotler BA; Spitalnik SL
PLoS One; 2020; 15(7):e0235807. PubMed ID: 32687543
[TBL] [Abstract][Full Text] [Related]
9. Successful management of severe Kell alloimmunization in pregnancy with intravenous immune globulin.
Patris M; Holoye A; Goldman D; De Coninck C; Colard M
Transfus Apher Sci; 2024 Apr; 63(2):103868. PubMed ID: 38238203
[TBL] [Abstract][Full Text] [Related]
10. Application of anti-D immunoglobulin in D-negative pregnant women in China.
Fu L; Ma C; Yu Y
Transfus Clin Biol; 2024 Feb; 31(1):41-47. PubMed ID: 38007217
[TBL] [Abstract][Full Text] [Related]
11. Low titer group O whole blood and risk of RhD alloimmunization: Rationale for use in Finland.
Susila S; Ilmakunnas M; Lauronen J; Vuorinen P; Ångerman S; Sainio S
Transfusion; 2024 May; 64 Suppl 2():S119-S125. PubMed ID: 38240146
[TBL] [Abstract][Full Text] [Related]
12. Guideline No. 448: Prevention of Rh D Alloimmunization.
Fung-Kee-Fung K; Wong K; Walsh J; Hamel C; Clarke G
J Obstet Gynaecol Can; 2024 Apr; 46(4):102449. PubMed ID: 38553007
[TBL] [Abstract][Full Text] [Related]
13. Preventing RhD haemolytic disease of the newborn. RhD negative women who have intrauterine death may need anti-D immunoglobulin.
Fox R
BMJ; 1998 Apr; 316(7138):1164-5. PubMed ID: 9569416
[No Abstract] [Full Text] [Related]
14. Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis.
Koelewijn JM; de Haas M; Vrijkotte TG; van der Schoot CE; Bonsel GJ
BJOG; 2009 Sep; 116(10):1307-14. PubMed ID: 19538414
[TBL] [Abstract][Full Text] [Related]
15. Hemolytic disease of the fetus and newborn: rapid review of postnatal care and outcomes.
de Winter DP; Kaminski A; Tjoa ML; Oepkes D; Lopriore E
BMC Pregnancy Childbirth; 2023 Oct; 23(1):738. PubMed ID: 37853331
[TBL] [Abstract][Full Text] [Related]
16. Rh immune globulin immunoprophylaxis after RhD-positive red cell exposure in RhD-negative patients via transfusion: A survey of practices.
Lu W; Stephens L; Shmookler A; O'Brien K; Karp JK; Hermelin D; Bakhtary S; Almozain N; George M; Fung M
Transfusion; 2024 May; 64(5):839-845. PubMed ID: 38534065
[TBL] [Abstract][Full Text] [Related]
17. Case of Hemolytic Disease of the Fetus and Newborn Treated Without Blood Products.
Hirschman L; Munchel A
J Pediatr Hematol Oncol; 2024 Jan; 46(1):e118-e120. PubMed ID: 38032187
[TBL] [Abstract][Full Text] [Related]
18. Rh isoimmunization in Sub-Saharan Africa indicates need for universal access to anti-RhD immunoglobulin and effective management of D-negative pregnancies.
Osaro E; Charles AT
Int J Womens Health; 2010 Dec; 2():429-37. PubMed ID: 21270966
[TBL] [Abstract][Full Text] [Related]
19. Erythrokinetic mechanism(s) causing the "late anemia" of hemolytic disease of the fetus and newborn.
Christensen RD; Bahr TM; Ohls RK; Ilstrup SJ; Moise KJ; Lopriore E; Meznarich JA
J Perinatol; 2024 Jun; 44(6):916-919. PubMed ID: 38216678
[TBL] [Abstract][Full Text] [Related]
20. Current Insights Into K-associated Fetal Anemia and Potential Treatment Strategies for Sensitized Pregnancies.
Carpenter MC; Souter SC; Zipkin RJ; Ackerman ME
Transfus Med Rev; 2024 Jan; 38(1):150779. PubMed ID: 37926651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
